CRINETICS PHARMACEUTICALS IN (CRNX) Stock Price, Forecast & Analysis
USA - NASDAQ:CRNX - US22663K1079 - Common Stock
CRNX Key Statistics, Chart & Performance
The current stock price of CRNX is 40 USD. In the past month the price decreased by -10.97%. In the past year, price decreased by -34.09%.
CRNX Latest News, Press Relases and Analysis
CRNX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 42.04 | 874.88B | ||
| JNJ | JOHNSON & JOHNSON | 17.97 | 449.32B | ||
| MRK | MERCK & CO. INC. | 9.79 | 215.51B | ||
| PFE | PFIZER INC | 7.63 | 138.90B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.12 | 95.03B | ||
| ZTS | ZOETIS INC | 18.97 | 53.29B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.38 | 22.49B | ||
| VTRS | VIATRIS INC | 4.34 | 11.80B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.39 | 10.68B | ||
| CORT | CORCEPT THERAPEUTICS INC | 83.77 | 7.77B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 6.89B | ||
| LGND | LIGAND PHARMACEUTICALS | 27.78 | 3.97B |
Related stock screener links
About CRNX
Company Profile
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company is headquartered in San Diego, California and currently employs 437 full-time employees. The company went IPO on 2018-07-18. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
Company Info
CRINETICS PHARMACEUTICALS IN
6055 Lusk Blvd.
San Diego CALIFORNIA 92121 US
CEO: R. Scott Struthers
Employees: 437
Phone: 18584506464
CRINETICS PHARMACEUTICALS IN / CRNX FAQ
What does CRINETICS PHARMACEUTICALS IN do?
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company is headquartered in San Diego, California and currently employs 437 full-time employees. The company went IPO on 2018-07-18. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
What is the stock price of CRINETICS PHARMACEUTICALS IN today?
The current stock price of CRNX is 40 USD. The price decreased by -8.02% in the last trading session.
Does CRINETICS PHARMACEUTICALS IN pay dividends?
CRNX does not pay a dividend.
How is the ChartMill rating for CRINETICS PHARMACEUTICALS IN?
CRNX has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about CRINETICS PHARMACEUTICALS IN (CRNX) stock?
23 analysts have analysed CRNX and the average price target is 83.93 USD. This implies a price increase of 109.83% is expected in the next year compared to the current price of 40.
Can you provide the market cap for CRINETICS PHARMACEUTICALS IN?
CRINETICS PHARMACEUTICALS IN (CRNX) has a market capitalization of 3.77B USD. This makes CRNX a Mid Cap stock.
What is the Short Interest ratio of CRINETICS PHARMACEUTICALS IN (CRNX) stock?
The outstanding short interest for CRINETICS PHARMACEUTICALS IN (CRNX) is 13.65% of its float.
CRNX Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to CRNX. When comparing the yearly performance of all stocks, CRNX turns out to be only a medium performer in the overall market: it outperformed 67.57% of all stocks.
CRNX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CRNX. CRNX has a great financial health rating, but its profitability evaluates not so good.
CRNX Financial Highlights
Over the last trailing twelve months CRNX reported a non-GAAP Earnings per Share(EPS) of -4.53. The EPS decreased by -21.45% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -28.68% | ||
| ROE | -31.57% | ||
| Debt/Equity | 0 |
CRNX Forecast & Estimates
23 analysts have analysed CRNX and the average price target is 83.93 USD. This implies a price increase of 109.83% is expected in the next year compared to the current price of 40.
For the next year, analysts expect an EPS growth of -32.76% and a revenue growth 212.74% for CRNX